Treatment

New data showed promising results for daraxonrasib, a new oral drug designed to treat metastatic pancreatic cancer driven by RAS mutations. Researchers described the treatment as a major advance because KRAS mutations, found in more than 90% of pancreatic cancers, were long considered difficult to target with drugs. Daraxonrasib works differently from earlier KRAS inhibitors. […]

Final results from the Phase 2 PRIMO trial showed that duvelisib (Copiktra) produced strong responses in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). The treatment achieved an overall response rate of 48%, higher than the 25% to 30% typically seen with many single-agent therapies. Complete responses were reported in 33.3% of patients. Results

A recent roundtable discussion highlighted the growing number of treatment options for pancreatic neuroendocrine tumors (pNETs), with therapy choices depending on whether the goal is disease control or tumor shrinkage. Targeted therapies such as everolimus and sunitinib are mainly used to stabilize disease. In the RADIANT-3 trial, everolimus improved progression-free survival to 11 months compared

In the study of 55 patients, the drug achieved a major response rate of 61.8% and an overall response rate of 83.6%, with disease control in 98.2% of patients. Responses were durable, with a median duration of 17.8 months and median progression-free survival of 13.5 months. The treatment also performed well in high-risk patients, including

Updated results from the Phase 1 REO 022 trial show that pelareorep (Reolysin), an oncolytic virus, combined with bevacizumab and FOLFIRI, may significantly improve outcomes in KRAS-mutant metastatic colorectal cancer. Patients receiving the combination had a response rate of 33% and a median duration of response of 19.5 months, far better than typical results with

Final results show that the combination of nivolumab and cabozantinib remains highly effective for patients with advanced renal cell carcinoma in real-world settings. The study reported strong outcomes, with a 74% overall survival rate at 18 months. Patients had a median progression-free survival of 14 months, and the overall response rate reached 62.1%, with disease

The ACCESS trial shows that stem cell transplants no longer require a perfect donor match. Using post-transplant cyclophosphamide (PTCy), patients with mismatched unrelated donors achieved a 74.2% two-year survival rate without higher risks of chronic graft-versus-host disease or relapse. Even 7/8, 6/8, or 5/8 matches can now be effective. This approach has greatly expanded access

Long-term data and molecular monitoring are reshaping treatment for hormone receptor–positive breast cancer, with a stronger focus on personalized and proactive care. Results from the NATALEE trial show that adding ribociclib to endocrine therapy reduces recurrence in early-stage disease. At four years, invasive disease-free survival was 88.5% with ribociclib versus 83.6% without, and the benefit

Five-year results show that tebentafusp (Kimmtrak) significantly improves long-term survival in patients with HLA-A*02:01–positive metastatic uveal melanoma. Historically, fewer than 10% of these patients survive five years, but tebentafusp increased the rate to 16%, compared to 8% with standard treatments such as pembrolizumab. Median overall survival also improved to 21.6 months versus 16.9 months, with

A new Phase 1b trial shows promising results for LYT-200, a first-in-class monoclonal antibody targeting galectin-9 in high-risk blood cancers. The drug is being tested in patients with relapsed or refractory myeloid malignancies who have already failed multiple treatments. In high-risk myelodysplastic syndrome, LYT-200 combined with standard therapy achieved a 45.5% overall response rate, with